Clinical Trial Update: A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment [Phase 4]

View source ↗

Summary

A phase 4 trial evaluating aflibercept injected into the eye at customized treatment intervals for neovascular age-related macular degeneration was terminated, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Neovascular (Wet) Age-related Macular Degeneration | Phase 4 | Status: TERMINATED | Results posted: 2024-10-16